Title Announcement Number Activity Code Clinical Trials Status Expiration Date Sort descending Program Official Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-25-070 (R21 Clinical Trial Not Allowed) R21 Clinical Trial Not Allowed 01/08/2027 Edward Sauter, M.D., Ph.D. Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-25-069 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/08/2027 Edward Sauter, M.D., Ph.D. National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis PAR-25-081 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/08/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H. Cancer Prevention and Control Clinical Trials Grant Program PAR-25-167 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/08/2027 Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research NOT-CA-24-074 01/08/2027 Nancy J. Emenaker, Ph.D., RDN, LD, FAND The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research PAR-24-153 (K12 Clinical Trial Optional) K12 Clinical Trial Optional 02/19/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H. Enhancing Mechanistic Research on Precision Probiotic Therapies PAR-25-211 (R61/R33 Clinical Trial Optional) R61, R33 Clinical Trial Optional 06/03/2027 Gabriela Riscuta, M.D., CNS Notice of Correction to PAR-25-104, Cancer Prevention and Control Clinical Trials Planning Grant Program NOT-CA-25-023 (R34 Clinical Trials Optional) R34 10/26/2027 Goli Samimi, Ph.D., M.P.H. Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-25-103 (U34 Clinical Trials Optional) U34 10/26/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H. Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-25-104 (R34 Clinical Trials Optional) R34 10/26/2027 Goli Samimi, Ph.D., M.P.H. Pagination 1 2 Next › Next page Last » Last page